The Lancet: Gastroenterology & Hepatology — Boerekamps A, et al. | March 11, 2019
In The Dutch Acute hepatitis C virus (HCV) in HIV study number 2 (DAHHS2) study, a single-arm, open-label, multicentre, phase 3b trial, researchers evaluated the effectiveness of grazoprevir plus elbasvir treatment in acute HCV infection and examined if treatment can be shortened during the acute phase of HCV infection. For the treatment of acute HCV genotype 1 or 4 infection, 8 weeks of grazoprevir plus elbasvir was highly effective. The ability to treat acute HCV immediately after diagnosis could help doctors achieve the HCV elimination goal of the WHO by 2030. A new sexually transmitted infection was the most common reported adverse event.